KCM
PRLD icon

Kennedy Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Kennedy Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,283
Closed -$134K – 724
2024
Q2 		$134K Buy
35,283
+10,248
+41% +$41.7K ﹤0.01% 690
2024
Q1 		$119K Buy
+25,035
New +$97.4K ﹤0.01% 716

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kennedy Capital Management's PRLD Position: Q3 2024 in Review

Kennedy Capital Management sold out of Prelude Therapeutics (PRLD) in Q3 2024, closing a stake of 35,283 shares — an estimated $134K sold.

Kennedy Capital Management first reported a position in PRLD in Q1 2024 and held it in 2 quarters. The position peaked at $134K in Q2 2024. 70 funds tracked by Wall St. Rank hold PRLD as of Q3 2024.

  • Kennedy Capital Management reported no remaining Prelude Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 35,283 Prelude Therapeutics shares in Q3 2024, an estimated $134K.
  • Kennedy Capital Management first reported a position in Prelude Therapeutics in Q1 2024 and held it in 2 quarters.
  • Kennedy Capital Management's Prelude Therapeutics position peaked at $134K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2024.

Based on Kennedy Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.